Podcasts about neuropsychiatric

Eboni Cornish, MD, joins Integrative Practitioner Content Specialist Avery St. Onge to discuss how to use SPECT imaging as a diagnostic tool to evaluate and manage chronic infections in a live interview at the 2025 Integrative Healthcare Symposium. About the Expert Eboni Cornish, MD, a highly regarded physician, provides integrative medicine services to a diverse global patient community. Currently serving as the Functional Medicine Director of the Amen Clinics East Coast Division, she specializes in autoimmune diseases, hormone imbalances, Lyme disease, autism, environmental toxicity, gut imbalances, neurology, and various other chronic conditions. Employing a holistic approach, Dr. Cornish identifies the root causes of health issues within the body's biological systems, offering comprehensive treatment to both adults and children. Her treatment philosophy is integrative and evidence-based.

Welcome back to "The Phelan-McDermid Podcast: Sharing Research, Progress, and Hope"This is our third and final episode from our mini-series featuring the 2023 PMSF Grant Awardees! On this episode, Dr. Lauren is talking to Dr. Milena Andzelm from Boston Children's Hospital. She received the Shannon O'Boyle Memorial Neuropsychiatric Illness Grant for her grant titled “Investigating Immune and Autoimmune Mechanisms of Neuropsychiatric Decompensation in Phelan-McDermid syndrome.Tune in to learn more about how a clinical case during Dr. Andzelm's training inspired her research in immune functioning in Phelan-McDermid syndrome as well as learn about progress on her current project. You'll also get to hear more about the Phelan-McDermid Syndrome Neuropsychiatric Consultation Group! Dr. Andzelm is still recruiting for her study, so check out our Current Open Research page for your opportunity to participate! And remember - she's looking for individuals 10 years+ with and without a history of neuropsychiatric illness! https://pmsf.org/current-open-research/And for more information about our Neuropsychiatric Consultation Group, a provider-to-provider service, please check out the link below:https://pmsf.org/neuropsychiatric-consultation-group/

In this episode of Daily Value, we look at the latest research on B vitamins and their in neuropsychiatric disorders. A newly published meta-analysis suggests a causal relationship between B vitamin deficiencies and neuropsychiatric disorders. We will break down the scientific findings on B6, B12, and folate, shedding light on their roles in conditions like Parkinson's disease.Discussion Points:How recent genetic studies support a causal link between B vitamin deficiencies and mental health conditions.The role of B vitamins in reducing neurotoxicity and slowing brain atrophy.How vitamin B12 may protect against dopamine neuron loss and disease progression.Evidence linking low B6 levels to neurotransmitter imbalances and schizophrenia risk.The impact of folate on one-carbon metabolism and its protective role in neurodegeneration.https://www.sciencedirect.com/science/article/abs/pii/S0149763425000685#:~:text=In a meta-analysis of,beneficial for certain specific diseases.https://pubmed.ncbi.nlm.nih.gov/26757190/https://pubmed.ncbi.nlm.nih.gov/32257364/https://pubmed.ncbi.nlm.nih.gov/30858560/https://pubmed.ncbi.nlm.nih.gov/32424116/https://pubmed.ncbi.nlm.nih.gov/33941768/Support the show

In this episode Alex R. Kemper, MD, MPH, MS, FAAP, deputy editor of the journal Pediatrics, offers a bird's-eye view of the February issue. Hosts David Hill, MD, FAAP, and Joanna Parga-Belinkie, MD, FAAP, also talk to AAP President Susan J. Kressly, MD, FAAP, about how to help patients and families affected by Pediatric Acute Onset Neuropsychiatric Syndrome or PANS. For resources go to aap.org/podcast.

In this episode, Ayesha spoke with Amit Etkin, Founder, President and CEO of Alto Neuroscience, a company developing precision treatments for neuropsychiatric conditions. Alto Neuroscience is focused on designing candidates that target core brain processes in patient populations not adequately treated by currently available medications. Alto is currently pursuing candidates in major depressive disorder (MDD), bipolar depression and schizophrenia. Mental health disorders are a leading cause of disability globally. In the US alone, 1 in 5 people are living with a mental health disorder, with an estimated $280 billion spent on mental health services in the country in 2020. Despite significant need, the current standard of care consists of treatments that are ineffective for many patients. Dr. Amit Etkin founded Alto in 2019 and is the president, CEO and serves as chair of the company's board of directors. Prior to founding Alto, Dr. Etkin was a tenured professor of psychiatry and behavioral sciences at Stanford University, where he held multiple leading roles. His research contributions during his tenure at Stanford led to Dr. Etkin being awarded the National Institutes of Health (NIH) Director's Pioneer Award, the most competitive and prestigious NIH grant, and the first in history to be awarded in clinical psychiatry. He also received an Entrepreneur of the Year (EY) award. Tune into the episode to hear from Dr. Etkin about innovations in treatments for neuropsychiatric disorders at Alto Neuroscience. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

Neuron-Connect and Metropolitan Consulting proudly present this new podcast—a deep dive into the invisible yet life-altering impact of closed head injuries. Hosted by an experienced psychiatrist, this episode explores the complexities of mild to moderate traumatic brain injuries (TBI), where standard imaging like MRIs and CT scans often fall short in detecting the real damage. We discuss how clinical diagnoses, advanced tools like QEEG (Quantitative Electroencephalography), and cutting-edge therapies such as Neurofeedback (NFB) are reshaping how we understand and treat these injuries. Learn about the longitudinal nature of TBI, the limitations of conventional approaches, and how these innovations pave the way for better outcomes and clearer advocacy in legal and clinical settings. https://neuron-connect.com. https://myndhi.org Whether you're a healthcare professional, attorney, or simply interested in the science of the brain, this podcast offers compelling insights into the intersection of neuropsychiatry and the law. Don't miss this chance to discover how the future of brain injury care is being redefined.

In this episode of the In Vivo podcast, Peter Flynn, CEO of Arialys Therapeutics, discusses the exciting field of autoimmune neuropsychiatry and the company's monoclonal antibody, which it is investigating for the treatment of a rare condition called anti-NMDA receptor encephalitis and potentially other indications.

What does the body of evidence say about smoking cessation? Does counselling make a difference and, if so, what kind? Is vaping effective as a way to quit smoking? And did you know there are drugs that have been shown to help give up the habit? Chris attempts to pronounce their names and is left with one question: is his veranda clean?   Become a supporter of our show today either on Patreon or through PayPal! Thank you! http://www.patreon.com/thebodyofevidence/ https://www.paypal.com/donate?hosted_button_id=9QZET78JZWCZE   Email us your questions at thebodyofevidence@gmail.com.   Assistant researcher: Aigul Zaripova, MD Theme music: “Fall of the Ocean Queen“ by Joseph Hackl Rod of Asclepius designed by Kamil J. Przybos Chris' book, Does Coffee Cause Cancer?: https://ecwpress.com/products/does-coffee-cause-cancer   Obviously, Chris is not your doctor (probably). This podcast is not medical advice for you; it is what we call information.   References: Reducing vs. quitting smoking 1) Gerber Y, Myers V, Goldbourt U. Smoking reduction at midlife and lifetime mortality risk in men: a prospective cohort study. Am J Epidemiol. 2012 May 15;175(10):1006-12. doi: 10.1093/aje/kwr466. Epub 2012 Feb 3. PMID: 22306566. 2) Nina S. Godtfredsen, Claus Holst, Eva Prescott, Jørgen Vestbo, Merete Osler, Smoking Reduction, Smoking Cessation, and Mortality: A 16-year Follow-up of 19,732 Men and Women from the Copenhagen Centre for Prospective Population Studies, American Journal of Epidemiology, Volume 156, Issue 11, 1 December 2002, Pages 994–1001, https://doi.org/10.1093/aje/kwf150   Behavioural interventions for smoking cessation 3) Cahill K, Lancaster T, Green N. Stage-based interventions for smoking cessation. Cochrane Database Syst Rev. 2010 Nov 10;(11):CD004492. doi: 10.1002/14651858.CD004492.pub4. PMID: 21069681. 4) Stead LF, Koilpillai P, Fanshawe TR, Lancaster T. Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database Syst Rev. 2016 Mar 24;3(3):CD008286. doi: 10.1002/14651858.CD008286.pub3. PMID: 27009521; PMCID: PMC10042551. 5) Hartmann-Boyce J, Hong B, Livingstone-Banks J, Wheat H, Fanshawe TR. Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation. Cochrane Database Syst Rev. 2019 Jun 5;6(6):CD009670. doi: 10.1002/14651858.CD009670.pub4. PMID: 31166007; PMCID: PMC6549450. 6) Hartmann-Boyce J, Livingstone-Banks J, Ordóñez-Mena JM, Fanshawe TR, Lindson N, Freeman SC, Sutton AJ, Theodoulou A, Aveyard P. Behavioural interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev. 2021 Jan 4;1(1):CD013229. doi: 10.1002/14651858.CD013229.pub2. PMID: 33411338; PMCID: PMC11354481. 7) Anthenelli RM, Benowitz NL, West R, St Aubin L, McRae T, Lawrence D, Ascher J, Russ C, Krishen A, Evins AE. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet. 2016 Jun 18;387(10037):2507-20. doi: 10.1016/S0140-6736(16)30272-0. Epub 2016 Apr 22. PMID: 27116918.   Network meta-analysis of medications and e-cigarettes 8) Lindson N, Theodoulou A, Ordóñez-Mena JM, Fanshawe TR, Sutton AJ, Livingstone-Banks J, Hajizadeh A, Zhu S, Aveyard P, Freeman SC, Agrawal S, Hartmann-Boyce J. Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta‐analyses. Cochrane Database of Systematic Reviews 2023, Issue 9. Art. No.: CD015226. DOI: 10.1002/14651858.CD015226.pub2. Accessed 04 November 2024.  

In this extract of his presentation for IMMH 2023,, Dr. Robert Hedaya, Clinical Professor of Psychiatry at Georgetown University and founder of the Whole Psychiatry & Brain Recovery Center showcases his cutting edge HYLANE treatment protocol which has proved very successful in treating previously intractable psychiatric and neurological problems. With decades of experience in both conventional and functional psychiatry, Dr. Hedaya has developed a unique approach that combines functional medicine with cutting-edge technologies like hyperbaric oxygen,quantitative EEG (qEEG) and photobiomodulation therapy to optimise brain function and enhance treatment outcomes. Dr. Hedaya shares case studies, including one of a patient suffering from cognitive decline and prosopagnosia (facial blindness), who experienced remarkable recovery after combining functional medicine protocols with high-tech brain treatments. His insights highlight how these advanced methods can repair not only the biochemical terrain of the body but also the brain's function. Dr. Hedaya's approach offers hope for patients with complex psychiatric and neurological conditions by combining functional medicine with high-tech brain treatments to achieve optimal outcomes. His work demonstrates that when the brain's hardware (the structural - neurons and their synaptic and biochemical connections) and software (character, psychology, schemas, belief systems)) as well as the cloud (spirituality and psyche) are addressed together, patients can experience significant recovery even in conditions traditionally deemed untreatable. In this episode, you'll learn about: The limitations of conventional psychiatry and how functional medicine can provide more comprehensive treatment for neuropsychiatric disorders by treating underlying issues such as hormone imbalances, neuroinflammation, and environmental toxins. The role of quantitative EEG (qEEG) in diagnosing brain dysfunction and guiding targeted treatments like transcranial photobiomodulation (laser therapy). How HBOT (Hyperbaric Oxygen Therapy) can promote healing of the brain's hardware. The impact of traumatic brain injury (TBI) on mental health and how advanced therapies like hyperbaric oxygen and laser therapy can restore brain function. Highlights from a groundbreaking case study of reversing cognitive decline and facial blindness using HYLANE combination treatment  The success of combining personalised and layered treatments, including diet, gut healing, hormone therapy, detoxification and advanced brain technologies for better neuropsychiatric health. How qEEG can identify abnormal brain function that traditional scans may miss, providing more accurate diagnostic insights, and how qEEG-guided therapies can improve memory, word recall, and focus in patients with neurodegenerative disorders and cognitive decline. The role of advanced brain mapping technologies in targeting specific brain areas for personalised treatments. For further insights, visit www.mindhealth360.com – your comprehensive guide to mental well-being.   Guest's Social Media Channels: - Website: https://wholepsychiatry.com/ - Facebook: https://www.facebook.com/DrRobertHedaya/  - LinkedIn: https://www.linkedin.com/in/dr-robert-hedaya-84422379   Publications: - Understanding Biological Psychiatry   - The Antidepressant Survival Guide: The Clinically Proven Program to Enhance the Benefits and Beat the Side Effects of Your Medication   - Depression: Advancing the Treatment Paradigm Through Functional Medicine (Chapter in Textbook of Functional Medicine)    

The McCullough Report with Dr. Peter McCullough – The primary series of mRNA Pfizer-BioNTech COVID-19 Vaccine drove Lynnette Milakovich to the brink of life and death. She is a courageous former court reporter with a background history of mild depression who had her life turned upside down after two Pfizer mRNA COVID-19 vaccine injections. Previously, she was a fit marathon runner and felt she was in the...

The McCullough Report with Dr. Peter McCullough – The primary series of mRNA Pfizer-BioNTech COVID-19 Vaccine drove Lynnette Milakovich to the brink of life and death. She is a courageous former court reporter with a background history of mild depression who had her life turned upside down after two Pfizer mRNA COVID-19 vaccine injections. Previously, she was a fit marathon runner and felt she was in the...

BUFFALO, NY- August 7, 2024 – A new #research paper was #published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science), Volume 16, Issue 14 on July 26, 2024, entitled, “mTORC1 activation in presumed classical monocytes: observed correlation with human size variation and neuropsychiatric disease.” In this new study, researchers Karl Berner, Naci Oz, Alaattin Kaya, Animesh Acharjee, and Jon Berner from Woodinville Psychiatric Associates, Virginia Commonwealth University, University of Birmingham, University Hospitals Birmingham, and MRC Health Data Research UK, aimed to measure phosphorylated p70S6K, a marker for mTORC1 activity, in individuals with psychiatric disease to determine whether phosphorylated p70S6K could predict medication response. Their results showed that mTORC1 activity correlated highly with classical biometrics (height, macrocephaly, pupil distance) and specific neuropsychiatric disease profiles (anxiety and autism). “Our data suggest that human variability of mTORC1 gain of function observed during the differentiation of stem-like monocytes into vascular tissue-resident macrophages correlates with physical size, subsets of neuropsychiatric disease, and clinical ketamine or rapamycin response.” DOI - https://doi.org/10.18632/aging.206033 Corresponding author - Jon Berner - jonbernermd@gmail.com Video short - https://www.youtube.com/watch?v=EXzX6CjtAHc Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206033 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, ketamine, lithium, monocyte, mTORC1, rapamycin About Aging-US The mission of the journal is to understand the mechanisms surrounding aging and age-related diseases, including cancer as the main cause of death in the modern aged population. The journal aims to promote 1) treatment of age-related diseases by slowing down aging, 2) validation of anti-aging drugs by treating age-related diseases, and 3) prevention of cancer by inhibiting aging. (Cancer and COVID-19 are age-related diseases.) Please visit our website at https://www.Aging-US.com​​ and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

Contributor: Taylor Lynch, MD Educational Pearls: What is NMS? Neuroleptic Malignant Syndrome Caused by anti-dopamine medication or rapid withdrawal of pro-dopamenergic medications Mechanism is poorly understood Life threatening What medications can cause it? Typical antipsychotics Haloperidol, chlorpromazine, prochlorperazine, fluphenazine, trifluoperazine Atypical antipsychotics Less risk Risperidone, clozapine, quetiapine, olanzapine, aripiprazole, ziprasidone Anti-emetic agents with anti dopamine activity Metoclopramide, promethazine, haloperidol Not ondansetron Abrupt withdrawal of levodopa How does it present? Slowly over 1-3 days (unlike serotonin syndrome which has a more acute onset) Altered mental status, 82% of patients, typically agitated delirium with confusion Peripheral muscle rigidity and decreased reflexes. AKA lead pipe rigidity. (As opposed to clonus and hyperreflexia in serotonin syndrome) Hyperthermia (>38C seen in 87% of patients) Can also have tachycardia, labile blood pressures, tachypnea, and tremor How is it diagnosed? Clinical diagnosis, focus on the timing of symptoms No confirmatory lab test but can see possible elevated CK levels and WBC of 10-40k with a left shift What else might be on the differential? Sepsis CNS infections Heat stroke Agitated delirium Status eptilepticus Drug induced extrapyramidal symptoms Serotonin syndrome Malignant hyperthermia What is the treatment? Start with ABC's Stop all anti-dopaminergic meds and restart pro-dopamine meds if recently stopped Maintain urine output with IV fluids if needed to avoid rhabdomyolysis Active or passive cooling if needed Benzodiazapines, such as lorazepam 1-2 mg IV q 4hrs What are active medical therapies? Controversial treatments Bromocriptine, dopamine agonist Dantrolene, classically used for malignant hyperthermia Amantadine, increases dopamine release Use as a last resort Dispo? Mortality is around 10% if not recognized and treated Most patients recover in 2-14 days Must wait 2 weeks before restarting any medications References Oruch, R., Pryme, I. F., Engelsen, B. A., & Lund, A. (2017). Neuroleptic malignant syndrome: an easily overlooked neurologic emergency. Neuropsychiatric disease and treatment, 13, 161–175. https://doi.org/10.2147/NDT.S118438 Tormoehlen, L. M., & Rusyniak, D. E. (2018). Neuroleptic malignant syndrome and serotonin syndrome. Handbook of clinical neurology, 157, 663–675. https://doi.org/10.1016/B978-0-444-64074-1.00039-2 Velamoor, V. R., Norman, R. M., Caroff, S. N., Mann, S. C., Sullivan, K. A., & Antelo, R. E. (1994). Progression of symptoms in neuroleptic malignant syndrome. The Journal of nervous and mental disease, 182(3), 168–173. https://doi.org/10.1097/00005053-199403000-00007 Ware, M. R., Feller, D. B., & Hall, K. L. (2018). Neuroleptic Malignant Syndrome: Diagnosis and Management. The primary care companion for CNS disorders, 20(1), 17r02185. https://doi.org/10.4088/PCC.17r02185 Summarized by Jeffrey Olson MS2 | Edited by Meg Joyce & Jorge Chalit, OMSIII  

It's hard for many to believe a tick bite or case of COVID can lead to severe mental illness, but we'll be hearing from someone on this episode of Raise the Line who lived through just that experience. Dr. Raven Baxter also happens to be the host of this special series on post-acute infection syndromes produced in collaboration with the Cohen Center for Recovery from Complex Chronic Illnesses at Mt. Sinai. While struggling with long COVID, Raven developed panic attacks and other mental health problems, and even though she explained to providers that she previously had no history of mental illness, there was reluctance to attribute the symptoms to her body's reaction to SARS‑CoV‑2. Unfortunately, this is not surprising to Dr. Shannon Delaney, a psychiatrist whose patients share similar stories. “People who are going through this can be suffering a lot, not only because of their symptoms, but because of invalidation from the medical community,” says Delaney, who believes brain inflammation caused by immune system dysregulation can explain why mental health issues emerge in this context. While Raven's other guest, Dr. Mike VanElzakker, concurs, his research at Massachusetts General Hospital and the PolyBio Research Foundation focuses on the vagus nerve as a contributing factor to symptoms of various types. “I would argue at least part of what people with these complex chronic illnesses are experiencing is an ongoing sickness response and that may be because there is a signal that's constantly bombarding the vagus nerve, which may be sensitized by inflammation.” This is an eye-opening look at mind-body connections that are challenging conventional wisdom.  Mentioned in this episode:Mount Sinai Health System Steven & Alexandra Cohen Foundation 

Episode 18: In this episode we talk to Holly about her ongoing journey through finding healing for her son who was diagnosed with Pediatric Acute-onset Neuropsychiatric. From the sudden onset of symptoms, advocating for him after being told he was a "normal" 2.5 year old and finally finding someone who could advise and help. We talk about what all set this on and what the day to day is like now.  Links for Holly's Episode: Lindsey Wells - PANS/PANDAS Expert Dr. Jill Crista - A Light in the Dark for PANDAS & PANS ASPIRE PANS - non-profit to improve the lives of people with PANS/PANDAS The PANDAS Docs - PANS/PANDAS Experts Resilience Naturopathic - Making PANS/PANDAS a thing of the past and making homeopathy a thing of the future  

En el episodio de hoy, os traigo un tema muy presente en neurorrehabilitación y en las consultas de neurología en relación con la esclerosis múltiple y es nada menos que la fatiga. La fatiga, ese síntoma tan temido desde siempre, tanto por pacientes como por profesionales de la salud, que es uno de los más reportados, con cifras de prevalencia entre 52 y el 90% de los pacientes (Nagaraj et al., 2013). Indagamos en la fisiopatología de la fatiga para entender mejor este fenómeno, también diferentes formas de ver la fatiga con sus distintas nomenclaturas o términos, vamos a ver cómo se suele evaluar en el entorno clínico y en investigación y finalmente daremos algunas pinceladas de tratamiento neuromodulador. Referencias del episodio: 1. Adibi, I., Sanayei, M., Tabibian, F., Ramezani, N., Pourmohammadi, A., & Azimzadeh, K. (2022). Multiple sclerosis-related fatigue lacks a unified definition: A narrative review. Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences, 27, 24. https://doi.org/10.4103/jrms.jrms_1401_20 (https://pubmed.ncbi.nlm.nih.gov/35419061/). 2. Ayache, S. S., & Chalah, M. A. (2017). Fatigue in multiple sclerosis - Insights into evaluation and management. Neurophysiologie clinique = Clinical neurophysiology, 47(2), 139–171. https://doi.org/10.1016/j.neucli.2017.02.004 (https://pubmed.ncbi.nlm.nih.gov/28416274/). 3. Ayache, S. S., Serratrice, N., Abi Lahoud, G. N., & Chalah, M. A. (2022). Fatigue in Multiple Sclerosis: A Review of the Exploratory and Therapeutic Potential of Non-Invasive Brain Stimulation. Frontiers in neurology, 13, 813965. https://doi.org/10.3389/fneur.2022.813965 (https://pubmed.ncbi.nlm.nih.gov/35572947/). 4. Bhattarai, J. J., Patel, K. S., Dunn, K. M., Brown, A., Opelt, B., & Hughes, A. J. (2023). Sleep disturbance and fatigue in multiple sclerosis: A systematic review and meta-analysis. Multiple sclerosis journal - experimental, translational and clinical, 9(3), 20552173231194352. https://doi.org/10.1177/20552173231194352 (https://pubmed.ncbi.nlm.nih.gov/37641617/). 5. Braley, T. J., & Chervin, R. D. (2010). Fatigue in multiple sclerosis: mechanisms, evaluation, and treatment. Sleep, 33(8), 1061–1067. https://doi.org/10.1093/sleep/33.8.1061 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2910465/). 6. Capone, F., Motolese, F., Falato, E., Rossi, M., & Di Lazzaro, V. (2020). The Potential Role of Neurophysiology in the Management of Multiple Sclerosis-Related Fatigue. Frontiers in neurology, 11, 251. https://doi.org/10.3389/fneur.2020.00251 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212459/). 7. Chalah, M. A., Riachi, N., Ahdab, R., Créange, A., Lefaucheur, J. P., & Ayache, S. S. (2015). Fatigue in Multiple Sclerosis: Neural Correlates and the Role of Non-Invasive Brain Stimulation. Frontiers in cellular neuroscience, 9, 460. https://doi.org/10.3389/fncel.2015.00460 (https://pubmed.ncbi.nlm.nih.gov/26648845/). 8. Chalah, M. A., Kauv, P., Créange, A., Hodel, J., Lefaucheur, J. P., & Ayache, S. S. (2019). Neurophysiological, radiological and neuropsychological evaluation of fatigue in multiple sclerosis. Multiple sclerosis and related disorders, 28, 145–152. https://doi.org/10.1016/j.msard.2018.12.029 (https://pubmed.ncbi.nlm.nih.gov/30594815/). 9. Dittner, A. J., Wessely, S. C., & Brown, R. G. (2004). The assessment of fatigue: a practical guide for clinicians and researchers. Journal of psychosomatic research, 56(2), 157–170. https://doi.org/10.1016/S0022-3999(03)00371-4 (https://pubmed.ncbi.nlm.nih.gov/15016573/). 10. Dobryakova, E., Genova, H. M., DeLuca, J., & Wylie, G. R. (2015). The dopamine imbalance hypothesis of fatigue in multiple sclerosis and other neurological disorders. Frontiers in neurology, 6, 52. https://doi.org/10.3389/fneur.2015.00052 (https://pubmed.ncbi.nlm.nih.gov/25814977/). 11. Freal, J. E., Kraft, G. H., & Coryell, J. K. (1984). Symptomatic fatigue in multiple sclerosis. Archives of physical medicine and rehabilitation, 65(3), 135–138 (https://pubmed.ncbi.nlm.nih.gov/6703889/). 12. Gaede, G., Tiede, M., Lorenz, I., Brandt, A. U., Pfueller, C., Dörr, J., Bellmann-Strobl, J., Piper, S. K., Roth, Y., Zangen, A., Schippling, S., & Paul, F. (2017). Safety and preliminary efficacy of deep transcranial magnetic stimulation in MS-related fatigue. Neurology(R) neuroimmunology & neuroinflammation, 5(1), e423. https://doi.org/10.1212/NXI.0000000000000423 (https://pubmed.ncbi.nlm.nih.gov/29259998/). 13. Garis, G., Haupts, M., Duning, T., & Hildebrandt, H. (2023). Heart rate variability and fatigue in MS: two parallel pathways representing disseminated inflammatory processes?. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 44(1), 83–98. https://doi.org/10.1007/s10072-022-06385-1 (https://pubmed.ncbi.nlm.nih.gov/36125573/). 14. Hanken, K., Eling, P., & Hildebrandt, H. (2014). The representation of inflammatory signals in the brain - a model for subjective fatigue in multiple sclerosis. Frontiers in neurology, 5, 264. https://doi.org/10.3389/fneur.2014.00264 (https://pubmed.ncbi.nlm.nih.gov/25566171/). 15. Iriarte, J., Subirá, M. L., & Castro, P. (2000). Modalities of fatigue in multiple sclerosis: correlation with clinical and biological factors. Multiple sclerosis (Houndmills, Basingstoke, England), 6(2), 124–130. https://doi.org/10.1177/135245850000600212 (https://pubmed.ncbi.nlm.nih.gov/10773859/). 16. Jaeger, S., Paul, F., Scheel, M., Brandt, A., Heine, J., Pach, D., Witt, C. M., Bellmann-Strobl, J., & Finke, C. (2019). Multiple sclerosis-related fatigue: Altered resting-state functional connectivity of the ventral striatum and dorsolateral prefrontal cortex. Multiple sclerosis (Houndmills, Basingstoke, England), 25(4), 554–564. https://doi.org/10.1177/1352458518758911 (https://pubmed.ncbi.nlm.nih.gov/29464981/). 17. Langeskov-Christensen, M., Heine, M., Kwakkel, G., & Dalgas, U. (2015). Aerobic capacity in persons with multiple sclerosis: a systematic review and meta-analysis. Sports medicine (Auckland, N.Z.), 45(6), 905–923. https://doi.org/10.1007/s40279-015-0307-x (https://pubmed.ncbi.nlm.nih.gov/25739555/). 18. Linnhoff, S., Fiene, M., Heinze, H. J., & Zaehle, T. (2019). Cognitive Fatigue in Multiple Sclerosis: An Objective Approach to Diagnosis and Treatment by Transcranial Electrical Stimulation. Brain sciences, 9(5), 100. https://doi.org/10.3390/brainsci9050100 (https://pubmed.ncbi.nlm.nih.gov/31052593/). 19. Liu, M., Fan, S., Xu, Y., & Cui, L. (2019). Non-invasive brain stimulation for fatigue in multiple sclerosis patients: A systematic review and meta-analysis. Multiple sclerosis and related disorders, 36, 101375. https://doi.org/10.1016/j.msard.2019.08.017 (https://pubmed.ncbi.nlm.nih.gov/31491597/). 20. Loy, B. D., Taylor, R. L., Fling, B. W., & Horak, F. B. (2017). Relationship between perceived fatigue and performance fatigability in people with multiple sclerosis: A systematic review and meta-analysis. Journal of psychosomatic research, 100, 1–7. https://doi.org/10.1016/j.jpsychores.2017.06.017 (https://pubmed.ncbi.nlm.nih.gov/28789787/). 21. Mills, R. J., & Young, C. A. (2008). A medical definition of fatigue in multiple sclerosis. QJM : monthly journal of the Association of Physicians, 101(1), 49–60. https://doi.org/10.1093/qjmed/hcm122 (https://pubmed.ncbi.nlm.nih.gov/18194977/). 22. Nagaraj, K., Taly, A. B., Gupta, A., Prasad, C., & Christopher, R. (2013). Prevalence of fatigue in patients with multiple sclerosis and its effect on the quality of life. Journal of neurosciences in rural practice, 4(3), 278–282. https://doi.org/10.4103/0976-3147.118774 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3821412/). 23. Patejdl, R., Penner, I. K., Noack, T. K., & Zettl, U. K. (2016). Multiple sclerosis and fatigue: A review on the contribution of inflammation and immune-mediated neurodegeneration. Autoimmunity reviews, 15(3), 210–220. https://doi.org/10.1016/j.autrev.2015.11.005 (https://pubmed.ncbi.nlm.nih.gov/26589194/). 24. Patejdl, R., & Zettl, U. K. (2022). The pathophysiology of motor fatigue and fatigability in multiple sclerosis. Frontiers in neurology, 13, 891415. https://doi.org/10.3389/fneur.2022.891415 (https://pubmed.ncbi.nlm.nih.gov/35968278/). 25. Torres-Costoso, A., Martínez-Vizcaíno, V., Reina-Gutiérrez, S., Álvarez-Bueno, C., Guzmán-Pavón, M. J., Pozuelo-Carrascosa, D. P., Fernández-Rodríguez, R., Sanchez-López, M., & Cavero-Redondo, I. (2022). Effect of Exercise on Fatigue in Multiple Sclerosis: A Network Meta-analysis Comparing Different Types of Exercise. Archives of physical medicine and rehabilitation, 103(5), 970–987.e18. https://doi.org/10.1016/j.apmr.2021.08.008 (https://pubmed.ncbi.nlm.nih.gov/34509464/). 26. Yang, T. T., Wang, L., Deng, X. Y., & Yu, G. (2017). Pharmacological treatments for fatigue in patients with multiple sclerosis: A systematic review and meta-analysis. Journal of the neurological sciences, 380, 256–261. https://doi.org/10.1016/j.jns.2017.07.042 (https://pubmed.ncbi.nlm.nih.gov/28870581/). 27. Zimek, D., Miklusova, M., & Mares, J. (2023). Overview of the Current Pathophysiology of Fatigue in Multiple Sclerosis, Its Diagnosis and Treatment Options - Review Article. Neuropsychiatric disease and treatment, 19, 2485–2497. https://doi.org/10.2147/NDT.S429862 (https://pubmed.ncbi.nlm.nih.gov/38029042/). 28. Zhou, X., Li, K., Chen, S., Zhou, W., Li, J., Huang, Q., Xu, T., Gao, Z., Wang, D., Zhao, S., & Dong, H. (2022). Clinical application of transcranial magnetic stimulation in multiple sclerosis. Frontiers in immunology, 13, 902658. https://doi.org/10.3389/fimmu.2022.902658 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9483183/).

This episode of the From Lab to Launch podcast, brought to you by Qualio, features Dr. Sam Clark, CEO of Terran Biosciences. With a background in neurosciences from MIT and an MD and PhD from Columbia University, Dr. Clark shares his journey from academia to leading a pioneering company in neuropsychiatric therapeutics. He discusses the challenges and innovations in the development and supply of GMP psychedelic compounds, highlighting how these substances are making significant strides toward transforming mental health treatment. Dr. Clark also explores Terran Biosciences' approach to overcoming drug development hurdles, emphasizing quality management and patent strategies to ensure the delivery of affordable, effective treatments. His insights offer a glimpse into the future of psychedelics in mainstream medicine and the broader implications for treating various disorders beyond mental health.https://terranbiosciences.com/ Dr. Sam Clark's LinkedIn: https://www.linkedin.com/in/sam-clark-md-phd-133139199/ 00:00 Welcome to From Lab to Launch!00:40 Introducing Dr. Sam Clark and Terran Biosciences01:23 Dr. Clark's Journey: From Academia to Neuropsychiatric Therapeutics02:48 The Renaissance of Psychedelic Therapeutics04:36 Challenges and Innovations in Drug Development08:36 Quality Management at Terran Biosciences10:23 The Future of Psychedelics in Mainstream Medicine12:46 Expanding Beyond Neuropsychiatry: Terran's Broader Impact14:02 Navigating Innovation and Ethics in Patenting17:48 Advice for Aspiring Scientists and Innovators20:42 Dr. Clark's Personal Inspirations and Closing Thoughts22:21 How to Follow Dr. Clark and Terran Biosciences23:00 Wrapping Up and How to Engage with From Lab to LaunchQualio website:https://www.qualio.com/ Previous episodes:https://www.qualio.com/from-lab-to-launch-podcast Apply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8 Music by keldez

Patients with good motor function outcomes after aneurysmal subarachnoid hemorrhage treatment may still be left with neuropsychiatric effects. They can suffer from such difficult conditions as cognitive dysfunction, depression and sexual dysfunction. Not all of these patients will volunteer their symptoms unprompted on follow-up. This outcome type has had limited study, and became an interest of today's guest, Dr. Jose Danilo Bengzon Diestro (1). JNIS editor-in-chief Dr. Felipe Albuquerque speaks with him on this subject, based on the recently published paper, "Long-term neuropsychiatric complications of aneurysmal subarachnoid hemorrhage: a narrative review".   (1) Department of Medicine, University of Toronto, Toronto, Canada   Please subscribe to the JNIS podcast on your favourite platform to get the latest podcast every month. If you enjoy our podcast, you can leave us a review or a comment on Apple Podcasts (https://apple.co/4aZmlpT) or Spotify (https://spoti.fi/3UKhGT5). We'd love to hear your feedback on social media - @JNIS_BMJ. Thank you for listening! This episode was produced and edited by Brian O'Toole. 

In episode 430 I chat with Edith Bell. Edith is a CBT Therapist and Director of Counselling for Familyworks Northern Ireland. We discuss her therapy story, PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections), what is PANDAS, working therapeutically with OCD brought on by PANDAS, what to look out for, Sydenham chorea, and much more. Hope it helps.  Show notes: https://theocdstories.com/episode/edith-430  The podcast is made possible by NOCD. NOCD offers effective, convenient therapy available in the US and outside the US. To find out more about NOCD, their therapy plans and if they currently take your insurance head over to https://go.treatmyocd.com/theocdstories Join our Patreon to see the video versions of the podcast ad-free and other perks: https://www.patreon.com/theocdstoriespodcast

Hui Yang is a returning VIP podcast guest. As an MD PhD in training, she recently completed her research track residency interviews with major academic medical centers and research institutes. She has observed an increased receptiveness and dedication to research on alternative nutraceutical strategies, including the ketogenic diet and increased animal meat/fat intake. She hopes to make the Carnivore.Diet community aware of this positive overall change and of certain specific academic centers that are actively pursuing this field. In addition, just recently, there have been major discoveries published in the journal Nature concerning the gut microbiome, the evolutionary history of genetic risks for multiple sclerosis and rheumatoid arthritis, and post-natal neuronal migration to the brain region most susceptible to Alzheimer's Disease. These discoveries are certainly important for those in academia. From her previous experiences, she knows they are also of interest to the Carnivore community. She hopes to bring one or more of these discoveries in an "easily digestible" language to their audience. Timestamps: 00:00 Trailer. 01:05 Introduction. 07:09 Study shows gluten-free diet benefits schizophrenia patients. 10:07 Study shows potential link between diet and schizophrenia. 13:15 Vitamin B for neuron balance and activation. 15:07 Exercise motivation and endurance tied to dopamine. 18:20 Restricted access to high-sugar food. 22:57 IgE and mast cells cause food allergies. 27:01 Anorexic effect in brain regions. 29:13 Perplexed by brain's activation on liking food. 31:13 PBM center signals satiety and aversion. Neuroscience tool discovery: PBN, CGRP neurons. 36:22 Complexity of autoimmune diseases and genetic evolution. 39:44 Scandinavians and Eurasians have high MS risk. 41:35 Comparison of MS genes in different populations. 44:42 Immune response, sanitation, and parasitic infections impact health. 48:12 Genetic risk increases likelihood of developing MS. 49:32 Doctors embracing ketogenic diet. 52:41 Where to find Hui. See open positions at Revero: https://jobs.lever.co/Revero/ Join Carnivore Diet for a free 30 day trial: https://carnivore.diet/join/ Carnivore Shirts: https://merch.carnivore.diet Subscribe to our Newsletter: https://carnivore.diet/subscribe/ . ‪#revero #shawnbaker #Carnivorediet #MeatHeals #HealthCreation   #humanfood #AnimalBased #ZeroCarb #DietCoach  #FatAdapted #Carnivore #sugarfree  ‪

Join us for part 2 of BrainStorm's interview with Dr. Pierre Tariot, former Director for Banner Alzheimer's Institute and Co-Director of The International Alzheimer's Prevention Project. Host Meryl Comer asks Dr. Tariot, who has devoted his career to the care and study of people with or at risk for Alzheimer's disease, about the neuropsychiatric features of dementia. Dr. Tariot highlights the advancements in understanding and treating these behaviors associated with Alzheimer's.  You won't want to miss this episode. This episode is sponsored by Otsuka and Lundbeck.Support the show

MedLink Neurology Podcast is delighted to feature selected episodes from BrainWaves, courtesy of James E Siegler MD, its originator and host. BrainWaves is an academic audio podcast whose mission is to educate medical providers through clinical cases and topical reviews in neurology, medicine, and the humanities, and episodes originally aired from 2016 to 2021. Originally released: April 19, 2018 What do Shel Silverstein, Bruce Willis, and French philosophy have in common? At least one thing. This week on the BrainWaves podcast we discuss the Cotard delusion and the legacy of the neurologist who described it. Produced by James E Siegler. Music by Andrew Sacco, Damiano Baldoni, Squire Tuck, Montplaisir, and Rafael Archangel. Voiceover by Erika Mejia. BrainWaves' podcasts and online content are intended for medical education only and should not be used for clinical decision-making. REFERENCESPearn J, Gardner-Thorpe C. Jules Cotard (1840-1889): his life and the unique syndrome which bears his name. Neurology 2002;58(9):1400-3. PMID 12011289Sahoo A, Josephs KA. A Neuropsychiatric analysis of the cotard delusion. J Neuropsychiatry Clin Neurosci 2018 Winter;30(1):58-65. PMID 28641497 We believe that the principles expressed or implied in the podcast remain valid, but certain details may be superseded by evolving knowledge since the episode's original release date.

Elisa Song, MD, joins Integrative Practitioner Content Specialist Avery St. Onge to discuss how understanding the underlying pathophysiology of leaky gut and leaky brain in children could inspire a new approach to treating pediatric neuropsychiatric conditions. This episode is brought to you by the Integrative Healthcare Symposium. Register for the Symposium and receive 15% off with promo code IPpodcast: https://www.xpressreg.net/register/ihsy0224/landing.php?sc=IPpodcast Learn more about the event by visiting the Symposium website: www.ihsymposium.com Contact the Integrative Healthcare Symposium team: info@ihsymposium.com Find us at integrativepractitioner.com or e-mail us at IPEditor@divcom.com. Theme music: "Upbeat Party" by Scott Holmes via freemusicarchive.org, "Carefree" by Kevin Mcleod via incompetech.com, and “Relaxing Light Background” by AudioCoffee. About the Expert Elisa Song, MD, is a Stanford-, NYU-, UCSF-trained integrative pediatrician, pediatric functional medicine expert, and mom to 2 thriving children. In her integrative pediatric practice, Whole Family Wellness (www.wholefamilywellness.org), she's helped 1000s of kids get to the root causes of their health concerns and empowered parents to help their children thrive – body, mind, and spirit – by integrating conventional pediatrics with functional medicine, homeopathy, acupuncture, herbal medicine, and essential oils. Dr. Song created Healthy Kids Happy Kids (www.healthykidshappykids.com) as an online holistic pediatric resource to help practitioners and parents bridge the gap between conventional and integrative pediatrics with an evidence-based, pediatrician-backed, mom-approved approach.

Dr. Arnie Mech, psychiatrist, talks about the importance of individualized patient diagnosis, the role of diet and genetic testing in mental health, the potential of novel treatments such as Transcranial Mandibular Stimulation (TMS), and the impact of sleep and nutrition on mental well-being. Recognizing the crucial interplay between the mind and body, they discuss the values of both the patient's journey and integrative psychiatry.Host: Bruce Bassi MDMore resources, including a full transcript, can be found at our podcast website: https://www.telepsychhealth.com/futurepsychiatrypodcast/We are always looking to grow and learn more about the field of tech and mental health. If you have an idea for the show, want to suggest a guest, or have a suggestion, please feel to message us through our website's contact page. If you want to support the show, please like on Facebook, and follow us on Instagram, and Tiktok and subscribe on Youtube.As always, the content is for educational purposes and is not medical advice. If you are having a medical or psychiatric emergency please contact 911.

In this Papers Podcast, Dr. Sam Chawner discusses his JCPP Advances paper ‘Neurodevelopmental dimensional assessment of young children at high genomic risk of neuropsychiatric conditions' (doi.org/10.1002/jcv2.12162). Sam is the first author of the paper. There is an overview of the paper, methodology, key findings, and implications for practice. Discussion points include: - What are copy-number variants (CNVs) and how they impact child development. - Insight into what 22q11.2 deletion syndrome is, how it is typically diagnosed, and how it is associated with psychiatric risk. - Implications for clinicians and CAMH professionals. - Whether there are adequate interventions targeted at early age groups. - Recommendations for prevention, detection, and the targeting of interventions.

Though many drug developers today are applying artificial intelligence and machine learning to accelerate and improve drug discovery, the results they produce, in part, may be limited to the quality of the data they are able to use. Nobias Therapeutics is not only using public and private data, but it boasts unique and proprietary access to one of the world's largest and most diverse pediatric genomic data sets to drive insights into human biology. The company's lead experimental therapy is a treatment for the rare condition 22q11.2 deletion syndrome, which is associated with a range of neuropsychiatric conditions. We spoke to Neil Inala, CEO of Nobias Therapeutics, about how AI is transforming drug discovery, the data Nobias is able to use to fuel its drug discovery, and the company's experimental therapy for the neuropsychiatric conditions associated with 22q11.2 deletion syndrome.

Are you familiar with the symptoms of Alzheimer's? Neuropsychiatric symptoms, or NPS, are mood and emotional symptoms of dementias and other brain diseases that are often overlooked and under-treated. This Alzheimer's Awareness Month, we're amplifying the voices of those experiencing NPS. Today, we're joined by Terry Montgomery, a friend of the alliance, a patient advocate, and someone who, after receiving a dementia diagnosis, has committed her voice to ensuring that Alzheimer's patients have access to treatments and care and that there's a nurturing community for everyone.

Join Our Online Education Community "The School of Doza" Here: https://community.schoolofdoza.com/   In this podcast episode, Nurse Doza discusses the common complaint of fatigue and offers insights into its possible causes. He emphasizes the importance of addressing fatigue, as it should not be a daily occurrence. He also recommends getting blood tests, particularly one for DHEAS, to assess adrenal function and the body's response to stress. He mentions that chronic stress, lack of sleep, and unhealthy lifestyle habits can contribute to fatigue. Nurse Doza encourages listeners to prioritize self-care, including good sleep and stress management, to improve their energy levels and overall health.   TIMESTAMPS: 00:00 START 05:50 Adrenal issues can cause fatigue. 11:46 Inflammation and fatigue are connected. 16:34 Address underlying causes of fatigue. 22:08 Check homocysteine levels for fatigue. 27:43 Sugar and inflammation decrease ATP. 32:15 Adrenal support supplement is recommended.     Looking for a boost in energy and mood? Discover Zen, MSW's premium adrenal support supplement. Packed with natural ingredients, it aids in balancing your hormones and combating fatigue. Elevate your health and regain that lost zest for life. Click here to check out Zen now!

The underlying regional neurobiology of the conditions may differ from person to person.

The underlying regional neurobiology of the conditions may differ from person to person.

In this episode of the Vibrant Wellness Podcast, Dr. Kevin Turner dives deep into functional medicine— inspired by his daughter's encounter with a pediatric neuropsychiatric condition. Joined by Dr. Kim Bruno, they discuss tickborne illnesses and related neuropsychiatric disorders in depth.They highlight the underestimated prevalence of tickborne infections and the challenges in treating Lyme disease, stressing the importance of comprehensive diagnosis and moving beyond just lab results. The discussion further expands on Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) and Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal infections (PANDAS), emphasizing the expertise needed to understand the multitude of factors affecting patients, especially when diagnosing adult PANS.The episode concludes with a compelling story of a woman's journey through, and recovery from, a tickborne disease. This story not only underscores the challenges of these illnesses but also brings hope to others facing similar situations. Dr. Turner details his treatment methods, including laser therapy, PEMF, and hyperbaric oxygen, highlighting the essential role of patient dedication.Tune in to understand the intertwined nature of tickborne diseases and their profound effects on neuropsychiatric well-being.Episode Chapters:(0:00:01) - Tickborne Illness and PANS Complexity(0:10:20) - Lyme Disease Treatment and Tick Illness(0:15:01) - Screening Patients and Utilizing Functional Medicine(0:25:49) - Understanding PANS and Autoimmune Encephalopathy(0:34:19) - Healthcare Mentorship and Case Reviews(0:43:53) - Wellness Centers and Vibrant Wellness PodcastLinks:Restorative Wellness Center: https://www.restorativechiro.com/Dr. Ashley Turner's Cookbooks: https://www.restorativechiro.com/drashleysbooksJoin Over 18,000 Leading Medical Professionals and Become a Vibrant Wellness Provider Today!

Today we're going to be talking about autoimmune issues, vaccines, and informed consent. This can be a sensitive topic for some and any content around vaccines that goes against the mainstream narrative is highly censored and hard to even find. The goal of this episode is not to change your mind or shame you for your decisions or views. I simply want to present you with a different side of the story and help empower you to make educated decisions about the health of yourself and your children. At the end of the day, whatever decision you make is right for you and that's okay. I believe our bodies have been incredibly designed. I believe medicine is also a wonderful tool to help our bodies when they need it. But I don't believe that everything coming from the side of “medicine” is true or safe. In this episode I share some of the things I've seen in my years of practice and my own personal experience with vaccines. I talk about how our immune systems are designed to work and how vaccines are designed to work as well as some of the myths and misinformation that is out there regarding vaccines and informed consent. My hope is that by listening to this episode you will have a glimpse into the whole picture and feel ready to do your own research in order to make your own decisions. Subscribe to our video podcast on YouTube: https://www.youtube.com/@dr.laurahanson4765 SHOW NOTES: https://connectmybrain.com/episode82 What do you want to learn more about? Submit your questions here: https://www.connectmybrain.com/survey/ Phone the office: 678-501-5172

Martha Sajatovic, MD explains how her research has led to a self-management program for patients with epilepsy and science to service models for other neurological conditions.

Dr. Kohlenberg and Dr. Rahman are both clinicians with expertise in neuropsychiatric illness in Phelan-McDermid syndrome. They discuss the first signs and symptoms, where to find treatment guidelines, how to connect your clinician with experts, and the difference between neuropsychiatric illness and regression. They discuss top research questions and progress. Kate points out where families can find key resources along the way. Dr. Kohlenberg is a pediatrician with decades of experience in child psychiatry. She is also mom to an adult daughter with PMS who was diagnosed as a result of neuropsychiatric illness, and Tesi has done a lot of work to understand how to best manage this for her daughter and many other people with PMS. She played a leadership role in starting the Neuropsych Consult Group, and is on PMSF's Medical Advisory Committee. Dr. Asif Rahman is a psychiatrist and is currently a fellow in Child and Adolescent Psychiatry on the Research Track at Mount Sinai. He is being funded by PMSF to do more research into neuropsychiatric illness in partnership with the Natural History Study and is being mentored by Dr. Alex Kolevzon.

Neuropsychiatric geneticist Dr. Jehannine Austin offers a fascinating insight into “bipolar gene” and “bipolar jar”, genetic and environmental factors that increase the risk for bipolar disorder, the latest in genetic testing for bipolar disorder, and what you should know before having children as a parent with bipolar disorder. Hosted by Dr. Erin Michalak. Dr. Jehannine Austin is the Executive director of the BC Mental Health and Substance Use Services Research Institute and Professor in Psychiatry & Medical Genetics. Dr. Austin is a board-certified genetic counselor and their research work involves studying the impact of genetic counseling for people with bipolar disorder and psychiatric disorders, and their families. Dr. Austin heads the Translational Psychiatric Genetics Group which includes the world's first specialist psychiatric genetic counselling service. Dr. Austin member of the College of the Royal Society of Canada, and a Fellow of the Canadian Academy of Health Sciences. Dr. Austin's work aims to make psychiatric genetics relevant to people with mental illness and their families by developing new counseling-based and biologically-based treatments. More on this episode: https://talkBD.live/genetics Translational Psychiatric Genetics Group (TPGG): https://bcchr.ca/TPGG National Society of Genetic Counselors: https://nsgc.org ⁠#talkBD⁠⁠⁠ gathers researchers, people with lived experience, healthcare providers, and top bipolar disorder experts from around the world to discuss and answer the most important questions about living with bipolar disorder. Learn more about the talkBD Bipolar Disorder Podcast and upcoming episodes at ⁠⁠⁠https://talkBD.live

Interview with Ye Ella Tian, MBBS, PhD, and Andrew Zalesky, PhD, authors of Evaluation of Brain-Body Health in Individuals With Common Neuropsychiatric Disorders. Hosted by John Torous, MD. Related Content: Evaluation of Brain-Body Health in Individuals With Common Neuropsychiatric Disorders

Interview with Ye Ella Tian, MBBS, PhD, and Andrew Zalesky, PhD, authors of Evaluation of Brain-Body Health in Individuals With Common Neuropsychiatric Disorders. Hosted by John Torous, MD. Related Content: Evaluation of Brain-Body Health in Individuals With Common Neuropsychiatric Disorders

Dr. Cameron discusses Neuropsychiatric Lyme disease in his new ebook "An Expert's Guide on Navigating Lyme disease."  This book summarizes his understanding of Lyme disease based on his first 600 Lyme disease science blogs and 35+ years of treating Lyme disease patients. The book includes over 200 published Lyme disease cases. Support his work by buying a copy of his ebook. His  ebook is only available on his website at https://danielcameronmd.com/store-navigating-lyme-disease/Or call Dr. Cameron's office at 914-666-4665.

Dr. Steve Feldman on behavioral economics - Hormonal IUDs and androgenic skin conditions - Acquired ichthyosis review - Isotretinoin improves neuropsychiatric outcomes - Connect with us! Web: https://dermaspherepodcast.com/ Twitter: @DermaspherePC Instagram: @dermaspherepodcast Facebook: https://www.facebook.com/DermaspherePodcast/ Check out Luke and Michelle's other podcast, SkinCast! https://healthcare.utah.edu/dermatology/skincast/ Luke and Michelle report no significant conflicts of interest… BUT check out our friends at: Kikoxp.com (a social platform for doctors to share knowledge) https://www.levelex.com/games/top-derm (A free dermatology game to learn more dermatology!) The University of Utah Dermatology Echo: https://physicians.utah.edu/echo/dermatology-primarycare

In this podcast episode, Marwan Sabbagh, MD, FAAN, and Marta San Luciano, MD, MS, FAAN, have a conversation about Parkinson's disease psychosis (PDP). Their discussion provides information on the disease itself—covering symptoms, risk factors, and mechanism—before moving into clinical strategies for diagnosis and disease and comorbidity management. The experts emphasize the importance of ruling out an underlying cause of psychosis before making a diagnosis of PDP, calling out common culprits such as urinary and respiratory tract infections. Following diagnosis, they comment on the value of implementing nonpharmacologic measures in tandem with pharmacologic interventions for PDP. Within the discussion of pharmacologic interventions, Drs Sabbagh and San Luciano give a well-rounded explanation of patient and medication factors they consider when choosing a treatment for their patients with PDP, including patient outcomes they have experienced in clinical practice. Rounding out the podcast, the experts touch on their approach to managing the very common comorbidity of sleep disturbances in patients with PDP.Presenters:Marwan Sabbagh, MD, FAANProfessor of NeurologyAlzheimer's and Memory Disorders DivisionDepartment of NeurologyBarrow Neurological InstitutePhoenix, ArizonaMarta San Luciano, MD, MS, FAANAssociate Professor of NeurologyUniversity of California, San FranciscoAttending NeurologistNeurology/Movement Disorders and Neuromodulation CenterUniversity of California, San Francisco Medical CenterSan Francisco, CaliforniaThis content is based on a CE/CME program supported by an independent educational grant from Acadia Pharmaceuticals, Inc.For additional activities in this program, visithttp://bit.ly/3tPMqnr

Episode Sponsor:This episode's Community Champion Sponsor is Catalyst. To virtually tour Catalyst and claim your space on campus, or host an upcoming event: CLICK HERE---Episode Overview: During this episode, Kelly Roman, CEO of Fisher Wallace Labs, a pioneering company in wearable prescription technology, joins us to discuss how his team is building industry-leading innovations that treat the brain electrically to reduce the symptoms of depression, anxiety, and insomnia. Additionally, Kelly shares how Fisher Wallace came to be, why he is so passionate about liberating people from depression, and his vision for wearable technology as the next frontier for mental health treatment. Join us to learn how Kelly and the Fisher Wallace team help treat neuropsychiatric disorders with novel wearable technology. Let's go!Episode Highlights:How Fisher Wallace came to be after a pivotal meeting with his co-founderReducing the cost of mental health treatment with Fisher Wallace's technologyConsumer feedback on Fisher Wallace's technologyWhy wearable devices are the next frontier for mental health treatmentAbout Our Guest: Kelly Roman is the Co-Founder & CEO of Fisher Wallace Labs. He has helped pioneer the prescription wearable category for more than a decade, with a proven track record in product development, regulatory affairs, and clinical trial strategy. Before co-founding Fisher Wallace, Kelly graduated from Harvard and served as an award-winning executive in the digital advertising and SaaS industries.Links Supporting This Episode:Fisher Wallace website: CLICK HEREKelly Roman LinkedIn page: CLICK HEREKelly Roman Twitter page: CLICK HEREMike Biselli LinkedIn page: CLICK HEREMike Biselli Twitter page: CLICK HEREVisit our website: CLICK HERESubscribe to newsletter: CLICK HEREGuest nomination form: CLICK HERE

It was my great pleasure to talk with Philip Mosley, who is one of the most experienced neuropsychiatrists working with DBS and published seminal work on non-motor, neuropsychiatric side-effects of subthalamic DBS in Parkinson's Disease as well as DBS for obsessive compulsive disorder when targeting the bed nucleus of the stria terminalis. Our conversation spans many areas from public health, remarkable individual case examples, the role of caregivers in DBS surgery, whether DBS could alter your personality, to boxing, raising three kids and a fast car. Phil has published certainly among the best network DBS papers on neuropsychiatric adverse events in notable journals, involving a virtual casino paradigm and investigating what differentiated patients that struggled with impulsivity and other side-effects after surgery from the ones that don't. After carrying out one of the few randomized clinical trials on DBS for OCD with the DBS team in Brisbane, Phil realized how critical access to this treatment option will be for some patients, so he has become active in pursuing the goal to broaden access to this treatment in Australia and beyond. After listening to the side of neurosurgeons, neurologists and psychiatrists on this podcast, I believe it is a very insightful change of perspective to hear from a neuropsychiatrist that has treated a large number of patients that underwent DBS – so I hope you enjoy this episode as much as I did the conversation with Phil!

In this episode, hear Marta Boffito, MD, PhD, FRCP, and Julian Falutz, MD, FRCPC, discuss their approach to minimizing antiretroviral (ARV)-related intolerances in older patients with HIV, including:Consequences of polypharmacyDeprescribing ARV and non-ARV medicationsComplications associated with aging (eg, geriatric syndromes such as falls, frailty, multimorbidity)Mediations to avoid, such as anticholinergic medications, to minimize drug–drug interactions and risk of developing geriatric syndromesFaculty:Marta Boffito, MD, PhD, FRCPConsultant Physician/ProfessorHIV/ResearchChelsea and Westminster HospitalImperial College LondonLondon, United KingdomJulian Falutz, MD, FRCPCAssociate Professor of MedicineDepartment of MedicineMcGill University School of MedicineDirectorComprehensive HIV and Aging InitiativeChronic Viral Illness ServiceMcGillMontreal, Quebec, CanadaLink to full program:https://bit.ly/3PM3nYeFollow along with the slides at:https://bit.ly/3NpAYI1

As we see more patients who have had Covid-19, we ask psychiatrist, Dr. Imaan Alaidroos, to speak with us about the neuropsychiatric impact of the disease. In this episode, Dr. Alaidroos outlines the treatments that are currently being studied for the neuropsychiatric symptoms of Covid-19. We also chat about the implications of these symptoms for the field of mental health. Hosts: Alan, Toshia Guest: Imaan Alaidroos, MD References: 7. Qureshi, A. I., Baskett, W. I., Huang, W., Shyu, D., Myers, D., Raju, M., Lobanova, I., Suri, M., Naqvi, S. H., French, B. R., Siddiq, F., Gomez, C. R., & Shyu, C. R. (2021). Acute Ischemic Stroke and COVID-19: An Analysis of 27 676 Patients. Stroke, 52(3), 905–912. https://doi.org/10.1161/STROKEAHA.120.031786 8. Helms J, Kremer S, MerdjiH, Clere-JehlR, Schenck M, KummerlenC, et al. Neurologic features in severe SARS-CoV-2 infection. N EnglJ Med. 2020;382:2268–2270. doi: 10.1056/NEJMc2008597. 9. FerrandoSJ, KlepaczL, Lynch S, TavakkoliM, DornbushR, BaharaniR, Smolin Y, Bartell A. COVID-19 psychosis: a potential new neuropsychiatric condition triggered by novel coronavirus infection and the inflammatory response? Psychosomatics. 2020;61:551–555. doi: 10.1016/j.psym.2020.05.012. 10. Parra A, JuanesA, LosadaCP, Álvarez-SesmeroS, Santana VD, Martí I, et al. Psychotic symptoms in COVID-19 patients. A retrospective descriptive study. Psychiatry Res. 2020;291:113254. doi: 10.1016/j.psychres.2020.113254. 11. Farooq, S., Tunmore, J., Wajid Ali, M., & Ayub, M. (2021). Suicide, self-harm and suicidal ideation during COVID-19: A systematic review. Psychiatry research, 306, 114228. https://doi.org/10.1016/j.psychres.2021.114228 12. Stefano, G. B., Büttiker, P., Weissenberger, S., Ptacek, R., Wang, F., Esch, T., Bilfinger, T. V., & Kream, R. M. (2021). Biomedical Perspectives of Acute and Chronic Neurological and Neuropsychiatric Sequelae of COVID-19. Current neuropharmacology, 10.2174/1570159X20666211223130228. Advance online publication. https://doi.org/10.2174/1570159X206662112231 13. de Erausquin, G. A., Snyder, H., Carrillo, M., Hosseini, A. A., Brugha, T. S., Seshadri, S., & CNS SARS-CoV-2 Consortium (2021). The chronic neuropsychiatric sequelae of COVID-19: The need for a prospective study of viral impact on brain functioning. Alzheimer's & dementia : the journal of the Alzheimer's Association, 17(6), 1056–1065. https://doi.org/10.1002/alz.12255 14. PashaeiY. Drug repurposing of selective serotonin reuptake inhibitors: Could these drugs help fight COVID-19 and save lives? J. Clin. Neurosci. 2021;88:163–172. doi: 10.1016/j.jocn.2021.03.010. 15. Dąbrowska, E., Galińska-Skok, B., & Waszkiewicz, N. (2021). Depressive and Neurocognitive Disorders in the Context of the Inflammatory Background of COVID-19. Life (Basel, Switzerland), 11(10), 1056. https://doi.org/10.3390/life11101056 Kępińska AP, Iyegbe CO, Vernon AC, Yolken R, Murray RM, Pollak TA. Schizophrenia and Influenza at the Centenary of the 1918-1919 Spanish Influenza Pandemic: Mechanisms of Psychosis Risk. Front Psychiatry. 2020 Feb 26;11:72. doi: 10.3389/fpsyt.2020.00072. PMID: 32174851; PMCID: PMC7054463.

As we see more patients who have had Covid-19, we ask psychiatrist, Dr. Imaan Alaidroos, to speak with us about the neuropsychiatric impact of the disease. In this episode, Dr. Alaidroos explains the mechanisms behind the neuropsychiatric symptoms and the specific neuropsychiatric symptoms that have been associated with Covid-19. Hosts: Alan, Toshia Guest: Imaan Alaidroos, MD References: 1.Méndez, R, Balanzá-Martínez, V, Luperdi, SC, Estrada, I, Latorre, A, González-Jiménez, P, Feced, L, Bouzas, L, Yépez, K, Ferrando, A, Hervás, D, Zaldívar, E, Reyes, S, Berk, M, Menéndez, R (La Fe University and Polytechnic Hospital, Valencia; Health Research Institute La Fe, Valencia; University of Barcelona, Barcelona, University of Valencia, CIBERSAM, Valencia; La Fe University and Polytechnic Hospital, Valencia; University of Valencia, Valencia; Health Research Institute La Fe, Valencia, Spain; Barwon Health, Deakin University, Geelong; The University of Melbourne, Melbourne, Victoria, Australia; Center for Biomedical Research Network in Respiratory Diseases (CIBERES), Madrid, Spain). Short-term neuropsychiatric outcomes and quality of life in COVID-19 survivors. J Intern Med 2021; 290: 621– 631. 2.Nakamura, Z. M., Nash, R. P., Laughon, S. L., & Rosenstein, D. L. (2021). Neuropsychiatric Complications of COVID-19. Current psychiatry reports, 23(5), 25. https://doi.org/10.1007/s11920-021-01237-9 3.Banerjee, D., & Viswanath, B. (2020). Neuropsychiatric manifestations of COVID-19 and possible pathogenic mechanisms: Insights from other coronaviruses. Asian journal of psychiatry, 54, 102350. https://doi.org/10.1016/j.ajp.2020.102350 4.Borah, P., Deb, P. K., Chandrasekaran, B., Goyal, M., Bansal, M., Hussain, S., Shinu, P., Venugopala, K. N., Al-Shar'i, N. A., Deka, S., & Singh, V. (2021). Neurological Consequences of SARS-CoV-2 Infection and Concurrence of Treatment-Induced Neuropsychiatric Adverse Events in COVID-19 Patients: Navigating the Uncharted. Frontiers in molecular biosciences, 8, 627723. https://doi.org/10.3389/fmolb.2021.627723 5.Jansen van Vuren, E., Steyn, S. F., Brink, C. B., Möller, M., Viljoen, F. P., & Harvey, B. H. (2021). The neuropsychiatric manifestations of COVID-19: Interactions with psychiatric illness and pharmacological treatment. Biomedicine & pharmacotherapy = Biomedecine& pharmacotherapie, 135, 111200. https://doi.org/10.1016/j.biopha.2020.111200 6.Roy, D., Ghosh, R., Dubey, S., Dubey, M. J., Benito-León, J., & Kanti Ray, B. (2021). Neurological and Neuropsychiatric Impacts of COVID-19 Pandemic. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 48(1), 9–24. https://doi.org/10.1017/cjn.2020.173

What are the neuropsychiatric effects of severe COVID-19? Find out this and more in today's PV Roundup podcast.

What are the neuropsychiatric effects of severe COVID-19? Find out this and more in today's PV Roundup podcast.

What are the neuropsychiatric effects of severe COVID-19? Find out this and more in today's PV Roundup podcast.

In part 2 of a 2 part series, Marco Mula, MD, PhD, FRCP, FEAN, discusses his article, "Neuropsychiatric and Cognitive Comorbidities in Epilepsy" from the April Continuum Epilepsy issue. This article and the accompanying Continuum Audio interview are available to subscribers at continpub.com/PsychCogEpilepsy.

In part 1 of a 2 part series, Marco Mula, MD, Ph.D., FRCP, FEAN, discusses his article, "Neuropsychiatric and Cognitive Comorbidities in Epilepsy" from the April Continuum Epilepsy issue. This article and the accompanying Continuum Audio interview are available to subscribers at continpub.com/PsychCogEpilepsy.